Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk stock reversed a three-day downtrend Wednesday after the weight-loss drugs kingpin leaned on Ozempic for a ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The Kokomo woman was pre-diabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

The International Day of Clean Energy on 26 January was declared by the General Assembly (resolution A/77/327) as a call to raise awareness and mobilize action for a just and inclusive transition ...

FILE - A dosage of Wegovy, March 1, 2024 in Front Royal ... didn’t learn about the state’s plans to change who can get GLP-1 treatment until a few days ago. “We just found this information out ...

Health Canada has issued a recall notice for compounded drugs containing semaglutide, which is a key component in popular medications like Ozempic and Wegovy ... in short supply but the ...

Then, weight loss was noticed as a significant side-effect - and Ozempic and Wegovy became household names. The study used data on US veterans with type 2 diabetes, some of whom were given Ozempic ...

For example, the epilepsy medicine topiramate or semaglutide, the active ingredient in Ozempic and Wegovy, may help people ... to go to “90 meetings in 90 days,” establish a routine, build ...